Stockmarket

Novartis sees annual sales growth of 4% until 2026



© Reuters. FILE PHOTO: A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo

ZURICH (Reuters) – Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.

Novartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.